Published in J Clin Endocrinol Metab on December 29, 2005
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. J Endocrinol Invest (2015) 1.98
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging (2008) 1.42
The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. PLoS One (2009) 1.11
Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol (2011) 1.07
Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol (2012) 0.95
Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2016) 0.94
Thyroid cancer: SEOM clinical guidelines. Clin Transl Oncol (2014) 0.93
Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging (2008) 0.91
Heath-related quality of life in thyroid cancer patients following radioiodine ablation. Health Qual Life Outcomes (2011) 0.89
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging (2011) 0.89
Role of surgeons in clinical trials for thyroid cancer. World J Surg (2007) 0.87
A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer. Eur Thyroid J (2013) 0.87
Endogenous TSH levels at the time of (131)I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur J Nucl Med Mol Imaging (2015) 0.87
Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. J Surg Res (2012) 0.86
Single photon emission computed tomography imaging for temporal dynamics of thyroidal and salivary radionuclide accumulation in 17-allyamino-17-demothoxygeldanamycin-treated thyroid cancer mouse model. Endocr Relat Cancer (2010) 0.85
Targeted radionuclide therapy. Cancers (Basel) (2011) 0.83
Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res (2010) 0.83
The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. J Korean Med Sci (2014) 0.82
Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol. Eur J Nucl Med Mol Imaging (2014) 0.82
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.82
Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review. Curr Oncol (2009) 0.81
One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.81
Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic differentiated thyroid carcinoma. J Thyroid Res (2011) 0.80
Clinical significance of discordant findings between pre-therapy (123)I and post-therapy (131)I whole body scan in patients with thyroid cancer. Int J Clin Exp Med (2013) 0.80
Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective. Endocrinol Metab (Seoul) (2015) 0.78
Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning. Eur J Nucl Med Mol Imaging (2008) 0.78
Age modifies the response to recombinant human thyrotropin. Thyroid (2010) 0.78
rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis. Nucl Med Commun (2013) 0.78
Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci (2017) 0.78
Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I(131) during Adolescence and Young Adulthood. Int J Endocrinol (2016) 0.78
Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study. PLoS One (2015) 0.77
Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Semin Nucl Med (2016) 0.77
Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer. J Thyroid Res (2012) 0.77
Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics (2009) 0.77
Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells. Thyroid (2014) 0.77
What role for recombinant human TSH in the treatment of metastatic thyroid cancer? Eur J Nucl Med Mol Imaging (2009) 0.77
Effects of Acute Recombinant Human TSH on Serum Ghrelin Levels. Front Endocrinol (Lausanne) (2011) 0.76
In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights (2011) 0.76
Pediatric papillary thyroid cancer: current management challenges. Onco Targets Ther (2016) 0.75
Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer. Asia Ocean J Nucl Med Biol (2013) 0.75
Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases. Eur Thyroid J (2014) 0.75
Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. Indian J Surg Oncol (2011) 0.75
Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. J Oncol (2016) 0.75
Radioactive iodine activities for postsurgical thyroid ablation: the lower the better. Eur Thyroid J (2013) 0.75
Comparison of Therapeutic Efficacy and Clinical Parameters Between Recombinant Human Thyroid Stimulating Hormone and Thyroid Hormone Withdrawal in High-Dose Radioiodine Treatment with Differentiated Thyroid Cancer. Nucl Med Mol Imaging (2014) 0.75
Radiotherapy: radioiodine in thyroid cancer-how to minimize side effects. Nat Rev Clin Oncol (2012) 0.75
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management. Onco Targets Ther (2009) 0.75
Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone. Medicine (Baltimore) (2015) 0.75
Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. Thyroid (2016) 0.75
A "new/old method" for TSH stimulation: could a third way to prepare DTC patients for (131)I remnant ablation possibly exist? Eur J Nucl Med Mol Imaging (2015) 0.75
Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer. Medicine (Baltimore) (2017) 0.75
ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging (2010) 0.75
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer. Endocr Rev (2017) 0.75
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. J Nucl Med (2017) 0.75
Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy. Ann Nucl Med (2017) 0.75
The role of nuclear medicine in differentiated thyroid cancer. Wien Med Wochenschr (2012) 0.75
Complications of endoscopic biliary sphincterotomy. N Engl J Med (1996) 11.10
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril (2001) 5.36
Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab (2001) 4.73
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics (1999) 4.07
Process of cellular division in Escherichia coli: physiological study on thermosensitive mutants defective in cell division. J Bacteriol (1973) 4.03
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med (1998) 3.98
Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA (1995) 3.68
A genetic linkage map for cattle. Genetics (1994) 3.64
EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging (2005) 3.61
Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer (1998) 3.55
Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect (1996) 3.34
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab (2003) 3.24
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology (1993) 3.18
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal (1997) 3.10
Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric (2001) 2.99
Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation (1996) 2.98
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Classification and management of perforations complicating endoscopic sphincterotomy. Surgery (1999) 2.63
PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet (1998) 2.62
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
[Recommendations and unanswered questions in the diagnosis and treatment of thyroid nodules. Opinion of the Thyroid Section of the German Society for Endocrinology]. Dtsch Med Wochenschr (2005) 2.45
Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab (2007) 2.45
The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol (1998) 2.44
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab (2015) 2.41
A prospective randomized comparison of endoscopic ultrasound- and computed tomography-guided celiac plexus block for managing chronic pancreatitis pain. Am J Gastroenterol (1999) 2.40
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
Thyroid cancer after Chernobyl. Nature (1992) 2.35
Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA (1996) 2.30
Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer (1993) 2.26
In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol (1999) 2.24
Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med (1993) 2.19
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int (2003) 2.13
Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab (1997) 2.11
Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology (1995) 2.11
[Effects of salts on the process of cell division in E. coli]. C R Acad Sci Hebd Seances Acad Sci D (1969) 2.11
Second primary malignancies in thyroid cancer patients. Br J Cancer (2003) 2.10
Role of conventional ultrasonography and color flow-doppler sonography in predicting malignancy in 'cold' thyroid nodules. Eur J Endocrinol (1998) 2.09
Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev (2000) 2.06
Failure of perchlorate to inhibit Tc-99m isonitrile binding by the thyroid during myocardial perfusion studies. Clin Nucl Med (1991) 2.05
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab (1994) 2.05
Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol (1997) 2.01
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy (2002) 1.97
Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. Sci Transl Med (2009) 1.97
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab (2000) 1.96
Serum haptoglobin: a novel marker of adiposity in humans. J Clin Endocrinol Metab (2004) 1.94
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
Video-assisted versus conventional parathyroidectomy in primary hyperparathyroidism: a prospective randomized study. Surgery (1999) 1.92
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study. Eur J Nucl Med (1999) 1.88
Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology (1999) 1.88
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab (2007) 1.87
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol (2008) 1.83
Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med (1989) 1.80
Recombination and nondisjunction in humans and flies. Hum Mol Genet (1996) 1.79
Pancreas divisum: results of minor papilla sphincterotomy. Gastrointest Endosc (1993) 1.79
Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer (2011) 1.78
Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology (1999) 1.78
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med (1996) 1.77
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab (2003) 1.75
Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc (1996) 1.73
Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab (2000) 1.73
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid (2001) 1.73
Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest (1995) 1.73
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging (2007) 1.71
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol (1996) 1.70
Smith-Lemli-Opitz syndrome-type II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality. Am J Med Genet (1987) 1.69
Intravenous cholangiography with helical CT: comparison with endoscopic retrograde cholangiography. Radiology (1994) 1.69
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol (2002) 1.68
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer. Ann Intern Med (2001) 1.68
Thyroid and other organ-specific autoantibodies in healthy centenarians. Lancet (1992) 1.68
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab (1999) 1.67
Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med (1995) 1.67